Snowden Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Snowden Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,405	Closed	-$497K	–	1145
2023 Q3	$497K	Buy	11,405 +4,075	+56%	+$145K	0.02%	659
2023 Q2	$265K	Sell	7,330 -16	-0.2%	-$659	0.01%	1002
2023 Q1	$273K	Buy	7,346 +244	+3%	+$11K	0.01%	974
2022 Q4	$322K	Buy	7,102 +1,840	+35%	+$119K	0.01%	893
2022 Q3	$367K	Buy	5,262 +1,813	+53%	+$134K	0.02%	795
2022 Q2	$231K	Buy	+3,449	New	+$219K	0.01%	981
2022 Q1	–	Sell	-550	Closed	-$80K	–	2158
2021 Q4	$80K	Buy	+550	New	+$85.4K	﹤0.01%	910

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Snowden Capital Advisors's MRTX Position: Q4 2023 in Review

Snowden Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 11,405 shares — an estimated $497K sold.

Snowden Capital Advisors first reported a position in MRTX in Q4 2021 and held it in 7 quarters. The position peaked at $497K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Snowden Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Snowden Capital Advisors sold 11,405 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $497K.
Snowden Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Snowden Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $497K in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Snowden Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.